Idenix Pharmaceuticals (IDIX) Reports In-Line Q4 Loss of 17c/Share

February 25, 2013 4:09 PM EST
Idenix Pharmaceuticals (NASDAQ: IDIX) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $327 thousand versus the consensus estimate of $740 thousand.

For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment